[
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2026",
    "title": "Årsredovisning 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a76a4c5117e3991ffc7424168f48001fe",
    "date": "2026-07-24",
    "period": "2026-annual",
    "form_type": "annual-report",
    "report_key": "2026:annual",
    "filename": "07231483.pdf",
    "text_chars": 270184,
    "sha256": "703dc9cf331cb86c3e871eef359c8c9e1f350bd66693297339ebc43f54cfbb50",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-001.html",
        "chars": 177508
      },
      {
        "number": 2,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-002.html",
        "chars": 92674
      }
    ]
  },
  {
    "doc_id": "mfn-fallback-kvartalsrapport-q4-2026",
    "title": "Kvartalsrapport Q4 2026",
    "source": "MFN fallback",
    "source_class": "mfn",
    "source_url": "https://mb.cision.com/Main/11664/4346191/4083691.pdf",
    "date": "2026-05-08",
    "period": "2026-q4",
    "form_type": "year-end-report",
    "report_key": "2026:q4",
    "filename": "4083691.pdf",
    "text_chars": 41933,
    "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
    "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
    "txt_url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/part-001.html",
        "chars": 41933
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6e7ef5729043f29a241ad7d874d6e332",
    "date": "2026-05-08",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "05070091.pdf",
    "text_chars": 41933,
    "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 41933
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a951a3c44992327bb2db77496fad2b858",
    "date": "2026-02-03",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "02035276.pdf",
    "text_chars": 42371,
    "sha256": "52422a673f021a36691639ade9117fa61ea8a8a88ba33670de0bfd53b34b609c",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 42371
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4170b2c5e7518f33330fe90c4bf9e7a3",
    "date": "2025-11-05",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "11044974.pdf",
    "text_chars": 48714,
    "sha256": "a03a4624f6bc622347d76c62bd8885b999eb9fe1f5ddf3b6f0ad7fcee82b230b",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 48714
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ab1555ee131c9a3524768cebab0234307",
    "date": "2025-08-08",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "08078305.pdf",
    "text_chars": 40050,
    "sha256": "e9144e3fb9d5c88ba59507b120d14abfad58884f283d9a57b055484a0b3abb39",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 40050
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a69387fbe38be4ed925cc34eb4f8b431e",
    "date": "2025-07-25",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "07243617.pdf",
    "text_chars": 268324,
    "sha256": "2041a192e045b1c51e308ed275f077ecb0a7b85b817d27175b61061e16060ea7",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 176774
      },
      {
        "number": 2,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 91548
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a1c2d5614926c2f3a4b7a6449e356924e",
    "date": "2025-05-08",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "05078976.pdf",
    "text_chars": 45447,
    "sha256": "5064cd8e9d54e23a20f7172bb0eb219d00f48d953223dc8841a4d9df4e5f873f",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 45447
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa2d7acdd1c8ac2d3da6749e231f2364f",
    "date": "2025-02-05",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "02041667.pdf",
    "text_chars": 42822,
    "sha256": "e9b7efd792d9f911a366e1328b400f5c7fa42b22ba5d5849f8b6f2af1d93d358",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 42822
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a491e4fc30d35b04dbb16ea9d2080b8a4",
    "date": "2024-11-06",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "11052871.pdf",
    "text_chars": 43765,
    "sha256": "d3a67c0326bd38a098dbc62a0ecab4df948b6a6769b3c8efa922fe6aab299fc5",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 43765
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a0a466069e69b7389d170f4dbd2a6c050",
    "date": "2024-08-08",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "08072800.pdf",
    "text_chars": 37269,
    "sha256": "088da055ed4b7355274205a6d0bbae3314c35955cc4561f42f7607f4e3e34b0e",
    "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 37269
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/eql-pharma",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 12679,
    "sha256": "754ee727fee795b2c12d399daef367b2e8a20783d1169e760afa0f9358370eec",
    "url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 12679
      }
    ]
  }
]